Agenda

7:30 a.m. Registration

8:00 a.m. Welcome and Introduction of Workshop Goals: Lucie Bruijn (ALSA); Alan Willard (NINDS); Amelie Gubitz (NINDS)

8:15 a.m. Updates from ALS and FTD Genetics Consortia
- ALS GWAS and Exome Sequencing: NIA-European Collaboration
  Bryan Traynor (National Institute on Aging)
- Project MinE: An International ALS Whole Genome Sequencing Initiative
  Leonard van den Berg (University Medical Centre Utrecht)
- Sequencing Efforts in ALS: University of Massachusetts Medical School
  John Landers (University of Massachusetts)
- ALS Early Results from Whole Exome Sequencing and the 1,000 Exomes Project, Chris Shaw (King's College London)
- ALS Exome Sequencing: Biogen Idec Genetics Consortium
  David Goldstein (Duke University)
- FTD GWAS and Whole Exome Sequencing
  Andy Singleton (National Institute on Aging)
- European Early-Onset Dementia (EU EOD) Consortium (includes FTLD and ALS)
  Christine van Broeckhoven (VIB, University of Antwerp)
- FTLD-TDP and FTLD-FUS Whole Genome Sequencing and PGRN GWAS
  Rosa Rademakers (Mayo Clinic)

10:00 a.m. Break

10:20 a.m. The Genetic FTD Initiative, GENFI
  Jonathan Rohrer (University College London, Institute of Neurology)

10:40 a.m. FTLD Module for the National Alzheimer's Coordinating Center
  David Knopman (Mayo Clinic)
11:00 a.m.  Clinical Assessment and Imaging Considerations in ALS and FTD
Moderated panel discussion
Panel members: Bradley Boeve (moderator, Mayo Clinic); Michael Benatar (University of Miami); Adriano Chio (University of Turin); Bradford Dickerson (Massachusetts General Hospital); Jonathan Rohrer (UCL Institute of Neurology); Alex Sherman (Massachusetts General Hospital)

12:15 p.m.  Lunch – sponsored by Biogen Idec

1:15 p.m.  C9orf72 Repeat Expansions: Molecules to Potential Mechanisms
Stuart Pickering-Brown (University of Manchester)

1:35 p.m.  Biomarkers and Therapeutic Approaches for C9orf72 Repeat Expansion Carriers
Leonard Petrucelli (Mayo Clinic)

1:55 p.m.  Approaches to Understand the Molecular Links between Genetic Subtypes of ALS and FTD
Peter Heutink (German Center for Neurodegenerative Diseases, DZNE)

2:15 p.m.  Insight into the Toxicity of ALS Disease Genes from a Simple Model Organism, Drosophila
Nancy Bonini (University of Pennsylvania)

2:35 p.m.  Break

2:50 p.m.  RNA Granule Dynamics and ALS/FTD
Paul Taylor (St. Jude Children's Research Hospital)

3:10 p.m.  Repeats and Structural Variants – Do We Need Alternatives to NGS?
Ammar Al Chalabi (King's College London)

3:30 p.m.  Optimizing the Utility of Genetic Data Sets
Moderated panel discussion
Panel members: David Goldstein (moderator, Duke University); Aaron Day-Williams (Biogen Idec); John Landers (University of Massachusetts); Mike Nalls (National Institute on Aging); Andy Singleton (National Institute on Aging); Stephan Züchner (University of Miami)

4:50 p.m.  Closing Remarks: Nadine Tatton (AFTD); Marg Sutherland (NINDS)

5:00 p.m.  Adjourn